Semaglutide Cut Calorie Intake for 60 Weeks in Trial

Clinical trial data indicates that semaglutide sustained a sizeable reduction in calorie consumption for more than a year, even as some early appetite-related sensations eased over time. Over a 60-week period, participants receiving the medication consumed 24% to 30% fewer calories than those given placebo, according to the findings.

The same dataset reported a clear difference in weight outcomes between groups. People assigned to semaglutide recorded an average weight loss of 15.1%, compared with 3.4% in the control group.

Trial results highlight sustained intake effects

The study separated subjective experience from measured eating behavior. While participants’ self-reported hunger and food preoccupation were found to normalize between weeks 40 and 60, the measured reduction in caloric intake continued through the 60-week mark.

Researchers said this pattern suggests that semaglutide’s impact on weight management can remain stable even when individuals no longer feel the same degree of appetite suppression they noticed earlier in treatment. In practical terms, the results point to a physiological component of reduced intake that persists beyond the initial phase of therapy.

How clinicians frame long-term use

Medical professionals emphasized that semaglutide is generally positioned as part of a broader weight-management approach rather than a standalone solution. The findings were described as supporting the clinical utility of longer-term administration for metabolic health and weight maintenance.

At the same time, clinicians cautioned that the medication works best when paired with ongoing dietary and lifestyle adjustments. They said a comprehensive strategy is used to support durable results and to reduce the risk of rebound weight gain after early progress.

What remains uncertain from the reported findings

The reported results focus on the persistence of reduced calorie intake and average weight change through week 60, alongside a shift in subjective hunger and food-related thoughts. The summary does not specify details such as participant characteristics, dosing schedules, adherence patterns, or how calorie intake was measured, which are factors that can influence how results apply across different patient populations.

Even with those unknowns, the central message of the trial data is consistent: semaglutide was associated with a 24% to 30% sustained reduction in caloric intake versus placebo over 60 weeks, and substantially larger average weight loss, while subjective appetite-related reports converged later in the study window.